Velomedix is developing a novel cooling approach to reduce Acute Myocardial Infarction (AMI) size and improve the clinical outcomes of heart attack patients. To provide these benefits in today’s clinical setting, a hypothermia technology must be able to cool patients rapidly enough to the target temperature of less than 35°C without significantly delaying the reopening of the blocked artery (i.e. extending door-to-balloon times).
The Velomedix technology cools patients quickly by circulating chilled fluid in the peritoneal cavity. This abdominal cavity contains multiple organs with high blood flow, providing a very large surface area for rapid heat transfer. Cooling directly at the body’s core versus the skin increases the effective cooling rate of the heart and brain. Together, these two factors allow the Velomedix technology to cool patients to therapeutic temperatures in less than 15 minutes.
While new for inducing therapeutic hypothermia, adding fluid to the peritoneal cavity is routinely and safely performed in peritoneal dialysis patients across the world. The Velomedix technique uses a similar approach but with the purpose of removing heat rather than metabolic products.
Additionally, the technology has the flexibility to fit into various AMI patient workflows. For instances in which a patient is brought immediately to the cath lab, catheter setup and cooling can be performed in parallel with standard patient preparation. If a patient starts in the emergency department instead, cooling can be started at that point, prior to transfer to the cath lab. Each hospital can choose which approach works best for their situation or leverage both depending on availability of the cath lab or specific patient situation.